<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jacobson, Anne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Fox, Keith A. A.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">ROCKET-AF: Rivaroxaban vs Warfarin in Patients with Moderate Renal Insufficiency</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">25-26</style></pages><abstract><style  face="normal" font="default" size="100%">Patients with atrial fibrillation and moderate renal dysfunction have a higher risk of stroke and bleeding than patients with normal renal function, but respond favorably to reduced-dose rivaroxaban compared with warfarin, according to new findings from the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibitor Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation [ROCKET-AF; NCT00403767].</style></abstract><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>